"I am excited to be part of the Genentech family where we are driving the drug development process through cutting-edge research, deepening our understanding of disease pathogenesis and translating this into clinical biomarker strategies."
I joined Genentech in the spring of 2014 as Scientist in the OMNI Biomarker Development group. Prior to joining Genentech, I worked in academic research and as director in a biotech startup active in target discovery in inflammatory, autoimmune and fibrotic diseases. In my current role, I am responsible for specific clinical biomarker strategies, in support of the development of medicines in inflammatory and autoimmune diseases both in small and large molecule programs. I am passionate about biomarkers and strongly believe they will deepen our understanding of the activity of molecular targets and disease pathogenesis, enabling decision-making in drug development.
I am also the biomarker lead in the inflammatory bowel disease franchise leading a team that outlines the overarching IBD biomarker strategy, focusing on preclinical and clinical biomarker discovery efforts across different disciplines. I enjoy working in cross-functional teams, which is central to my everyday job at Genentech and integral to successful drug development.
Curr Pharm Des. 2012;18(27):4093-102.
My focus as biomarker lead is to ensure that clinical biomarker strategies are in place in specific autoimmune and inflammatory therapeutic candidate programs – from early research to late stage. These biomarkers strategies encompass predictive, prognostic as well as pharmacodynamics biomarkers. Implementation of these biomarker strategies into clinical trials ranges from scientific exploration of biomarkers to implementing biomarker assays in clinical trials.